Emergent BioSolutions Inc. (EBS)
NYSE: EBS · Real-Time Price · USD
5.63
-0.25 (-4.25%)
At close: Aug 1, 2025, 4:00 PM
5.65
+0.02 (0.35%)
After-hours: Aug 1, 2025, 7:58 PM EDT
Altus Power Revenue
Emergent BioSolutions had revenue of $222.20M in the quarter ending March 31, 2025, a decrease of -26.03%. This brings the company's revenue in the last twelve months to $965.40M, down -18.56% year-over-year. In the year 2024, Emergent BioSolutions had annual revenue of $1.04B, down -0.54%.
Revenue (ttm)
$965.40M
Revenue Growth
-18.56%
P/S Ratio
0.31
Revenue / Employee
$1,072,667
Employees
900
Market Cap
305.58M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.04B | -5.70M | -0.54% |
Dec 31, 2023 | 1.05B | -68.20M | -6.10% |
Dec 31, 2022 | 1.12B | -656.10M | -36.99% |
Dec 31, 2021 | 1.77B | 196.30M | 12.45% |
Dec 31, 2020 | 1.58B | 471.30M | 42.61% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
EBS News
- 4 days ago - Emergent Applauds Availability of Over-the-Counter Naloxone in U.S. House of Representatives - GlobeNewsWire
- 4 days ago - New Publication in Expert Review of Anti-infective Therapy Evaluates Brincidofovir as Potential Antiviral Treatment for Mpox - GlobeNewsWire
- 18 days ago - Emergent BioSolutions to Report Second Quarter 2025 Financial Results on August 6, 2025 - GlobeNewsWire
- 24 days ago - Emergent BioSolutions Secures $51.9 Million Contract Modification Award for CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) as part of U.S. Biodefense Preparedness Efforts - GlobeNewsWire
- 4 weeks ago - Emergent BioSolutions Expands NARCANDirect® to Offer KLOXXADO® (naloxone HCl) Nasal Spray 8 mg and Convenience Kits Amid Changes in Overdose Death Rate - GlobeNewsWire
- 5 weeks ago - Emergent BioSolutions Secures $62.4 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Bolster U.S. Biodefense Supply - GlobeNewsWire
- 6 weeks ago - Emergent BioSolutions: Strategic Turnaround Proving Tricky, But I'm Still Hopeful - Seeking Alpha
- 6 weeks ago - Emergent BioSolutions Announces Addition to Russell 3000® Index - GlobeNewsWire